Cargando…
Is the BNT162b2 COVID-19 vaccine effective in elderly populations? Results from population data from Bavaria, Germany
BACKGROUND: The efficacy of the BioNTech-Pfizer BNT162b2 vaccination in the elderly (≥80 years) could not be fully assessed in the BioNTech-Pfizer trial due to low numbers in this age group. We aimed to evaluate the effectiveness of the BioNTech-Pfizer (BNT162b2) vaccine to prevent SARS-CoV-2 infect...
Autores principales: | Gomes, Delphina, Beyerlein, Andreas, Katz, Katharina, Hoelscher, Gabriele, Nennstiel, Uta, Liebl, Bernhard, Überla, Klaus, von Kries, Rüdiger |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8570490/ https://www.ncbi.nlm.nih.gov/pubmed/34739520 http://dx.doi.org/10.1371/journal.pone.0259370 |
Ejemplares similares
-
Newborn Hearing Screening in Bavaria—Is It Possible to Reach the Quality Parameters?
por: Brockow, Inken, et al.
Publicado: (2018) -
Virological COVID-19 surveillance in Bavaria, Germany suggests no SARS-CoV-2 spread prior to the first German case in January 2020
por: Eberle, Ute, et al.
Publicado: (2021) -
Detection and viral RNA shedding of SARS-CoV-2 in respiratory specimens relative to symptom onset among COVID-19 patients in Bavaria, Germany − Addendum
por: Woudenberg, Tom, et al.
Publicado: (2021) -
Screening for infectious diseases among newly arrived asylum seekers, Bavaria, Germany, 2015
por: Ackermann, Nikolaus, et al.
Publicado: (2018) -
Associations of area-level deprivation with adverse obstetric and perinatal outcomes in Bavaria, Germany: Results from a cross-sectional study
por: Beyerlein, Andreas, et al.
Publicado: (2020)